ImpediMed Limited (ASX: IPD) a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), is pleased to announce the presentation of an abstract at the American Society for Breast Surgeons (ASBrS) in Orlando, Florida.

Dr. Lyndsey Kilgore from The University of Kansas Cancer Center made an oral presentation on her work - Reducing Breast Cancer Related Lymphedema (BCRL) Through Prospective Surveillance Monitoring Using Bioimpedance Spectroscopy (BIS) and Patient Directed Self-Interventions.

Dr. Kilgore presented three conclusions to her study:

- Early detection using BIS with easy patient self-directed interventions for early stage lymphedema can significantly improve patient outcomes and decreased the development of persistent BCRL
- Prospective surveillance programs focusing on comprehensive education, early identification and intervention that emphasizes compression garments and self-massage can have a high success rate for reducing persistent BCRL
- Persistent BCRL may be a negative predictor for survival

The abstract, ASBrS press release and slide presentation can be accessed from the following links:


Richard Carreon
Managing Director & CEO

Media Contact:
Kyahn Williamson, WE Buchan
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au
About ImpediMed
Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.